AlphaTON grants Immunova option to acquire iOx Therapeutics subsidiary

AlphaTON announced today in New York that it has granted Immunova an exclusive option to acquire its subsidiary iOx Therapeutics, a strategic move aimed at optimizing the company's biotechnology portfolio and focusing on core research areas. The agreement represents a significant development in the biotech sector, potentially valued at several million dollars depending on future performance milestones. The transaction comes as AlphaTON continues to restructure its business operations to concentrate on its primary therapeutic areas. iOx Therapeutics, specializing in innovative immunotherapy solutions, has shown promising early-stage results but requires substantial investment to advance to clinical trials. Immunova, known for its expertise in immunology and oncology research, will have a specified period to exercise the option, during which due diligence and valuation processes will be completed. Industry analysts view this move as part of a broader trend in the biotechnology sector where companies strategically divest non-core assets to streamline operations and allocate resources more efficiently.